newsfilter
← Latest News
Business Wire·

TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO

TAGRISSO plus savolitinib extended median overall survival by nearly five months SAFFRON is first global Phase III trial to show significant progression-free and overall survival benefit in this setting, reinforcing